Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01219075 · ClinicalTrials.gov registry record · NA
Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer
A NA study, sponsored by University of Southern California.
- Completed
- Registry status
- NA
- Development phase
- 110
- Enrollment target
NCT01219075: Completed NA study, sponsored by University of Southern California.
NCT01219075 is a NA study that has completed, run by University of Southern California. The registered enrollment target is 110 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01219075, a NA study, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- NA
- Development phase
- 110 participants
- Enrollment target
Study Summary
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of soy isoflavones supplements may prevent or treat early stage breast cancer. PURPOSE: This clinical trial studies soy isoflavones supplementation in treating women at high risk for or with breast cancer.
Interventions
- OTHER placebo
- OTHER questionnaire administration
- PROCEDURE biopsy
- PROCEDURE magnetic resonance imaging
- DIETARY_SUPPLEMENT soy isoflavones
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2010-07-01 |
| Est. Completion | 2022-11-24 |
| Phase | NA |
What the finished NCT01219075 record still lists
NCT01219075 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 5 interventions - of which placebo is the first listed.
NCT01219075 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01219075 about?
NCT01219075 is a clinical study titled "Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer". RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of soy isoflavones supplements may prevent or treat early stage breast cancer. PURPOSE: This clinical trial studies soy isoflavones supplementation in treating women at high risk for or with breast cancer.
What is the current status of trial NCT01219075?
This trial is currently completed. It is a NA study. The enrollment target is 110 participants. The study started on 2010-07-01. Estimated completion is 2022-11-24.
What interventions are being tested in trial NCT01219075?
The interventions under investigation include: placebo (OTHER), questionnaire administration (OTHER), biopsy (PROCEDURE), magnetic resonance imaging (PROCEDURE), soy isoflavones (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01219075?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01219075's enrollment target sits among peer trials
110 816th of 2000 higher than 1,176 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI